Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Efficacy and Safety of PF-07038124 in Patients With Atopic Dermatitis and Plaque Psoriasis: A Randomized Clinical Trial.

JAMA dermatology·2023
Same author

Improving enteral nutrition tolerance and protein intake maybe beneficial to intensive care unit patients.

Scientific reports·2023
Same author

Efficacy and Safety of Dual Anti-HER2 Blockade and Docetaxel With or Without Carboplatin as Neoadjuvant Regimen for Treatment of HER2-Positive Breast Cancer.

Technology in cancer research & treatment·2023
Same author

Boosting Low-Temperature CO<sub>2</sub> Hydrogenation over Ni-based Catalysts by Tuning Strong Metal-Support Interactions.

Angewandte Chemie (International ed. in English)·2023
Same author

A new direction in Chinese herbal medicine ameliorates for type 2 diabetes mellitus: Focus on the potential of mitochondrial respiratory chain complexes.

Journal of ethnopharmacology·2023
Same author

Computational Insight into the Nature and Strength of the π-Hole Type Chalcogen∙∙∙Chalcogen Interactions in the XO<sub>2</sub>∙∙∙CH<sub>3</sub>YCH<sub>3</sub> Complexes (X = S, Se, Te; Y = O, S, Se, Te).

International journal of molecular sciences·2023
Same journal

Intermittent Theta-Burst Stimulation for Depression-Delineating Specific and Nonspecific Effects.

JAMA network open·2026
Same journal

Intermittent Theta-Burst Stimulation and Depressive Symptoms in Major Depressive Disorder: A Randomized Clinical Trial.

JAMA network open·2026
Same journal

Germline Multigene Panel Testing in Women With Invasive Lobular Cancer.

JAMA network open·2026
Same journal

Prevention of Surgical Site Contamination With Cutibacterium acnes During Cardiac Surgery: A Randomized Clinical Trial.

JAMA network open·2026
Same journal

Cost-Effectiveness of Universal Low-Dose Computed Tomographic Lung Cancer Screening in Singapore.

JAMA network open·2026
Same journal

Childhood Sexual Abuse and Rates of Loneliness in Adulthood.

JAMA network open·2026
See all related articles

Related Experiment Video

Updated: Apr 18, 2026

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
11:02

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Published on: October 30, 2013

21.9K

Clinical Outcomes in Bacillus Calmette-Guérin-Exposed Non-Muscle-Invasive Bladder Cancer.

Maria Giatsoglou1, Dimitrios Chatzistavrou1, Joan Mazzarelli Sopczynski2

  • 1Pfizer Artificial Intelligence, Data and Analytics Research and Development AI and Data Science, Thessaloniki, Greece.

JAMA Network Open
|April 16, 2026
PubMed
Summary
This summary is machine-generated.

Most patients with non-muscle-invasive bladder cancer (NMIBC) receiving Bacillus Calmette-Guérin (BCG) therapy experienced inadequate treatment, leading to higher rates of recurrence, progression, and cystectomy. This highlights a critical need for improved therapeutic strategies for BCG-exposed NMIBC patients.

More Related Videos

An Orthotopic Bladder Cancer Model for Gene Delivery Studies
07:48

An Orthotopic Bladder Cancer Model for Gene Delivery Studies

Published on: December 1, 2013

13.3K
Evaluation of the Efficacy of the H. pylori Protein HP-NAP as a Therapeutic Tool for Treatment of Bladder Cancer in an Orthotopic Murine Model
06:12

Evaluation of the Efficacy of the H. pylori Protein HP-NAP as a Therapeutic Tool for Treatment of Bladder Cancer in an Orthotopic Murine Model

Published on: May 29, 2015

7.7K

Related Experiment Videos

Last Updated: Apr 18, 2026

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
11:02

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Published on: October 30, 2013

21.9K
An Orthotopic Bladder Cancer Model for Gene Delivery Studies
07:48

An Orthotopic Bladder Cancer Model for Gene Delivery Studies

Published on: December 1, 2013

13.3K
Evaluation of the Efficacy of the H. pylori Protein HP-NAP as a Therapeutic Tool for Treatment of Bladder Cancer in an Orthotopic Murine Model
06:12

Evaluation of the Efficacy of the H. pylori Protein HP-NAP as a Therapeutic Tool for Treatment of Bladder Cancer in an Orthotopic Murine Model

Published on: May 29, 2015

7.7K

Area of Science:

  • Oncology
  • Urology

Background:

  • Bacillus Calmette-Guérin (BCG) is standard for non-muscle-invasive bladder cancer (NMIBC).
  • Many patients experience recurrence and progression despite BCG treatment.
  • Clinical adherence to recommended BCG regimens is often low.

Purpose of the Study:

  • To examine the clinical burden, treatment patterns, and outcomes of patients with BCG-exposed NMIBC in the US.
  • To identify disparities in BCG therapy adequacy and its impact on patient outcomes.
  • To underscore the need for novel therapeutic approaches for NMIBC.

Main Methods:

  • Retrospective cohort study using deidentified US electronic health records and insurance claims (2007-2024).
  • Identified NMIBC patients receiving at least one full BCG course.
  • Classified BCG therapy as adequate or inadequate induction and maintenance based on regulatory definitions.

Main Results:

  • Adequate BCG maintenance therapy was received by only 24.9% of patients.
  • Among patients with carcinoma in situ, 59.3% recurred within 24 months; 83.1% were BCG-exposed.
  • BCG-exposed patients accounted for the majority of disease progression (83.0%) and cystectomy cases (87.8%), particularly those with inadequate maintenance therapy.

Conclusions:

  • Patients with BCG-exposed NMIBC represent a large, underserved population.
  • The majority of NMIBC progression and cystectomy cases occurred in BCG-exposed patients.
  • Urgent need for new therapeutic strategies and clinical trial designs targeting BCG-exposed NMIBC.